ALX ONCOLOGY HOLDINGS INC
ALXODrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Evorpacept (ALX148)
Gastric Cancer
evorpacept
Head and Neck Cancer
ALX148
Ovarian Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Evorpacept (ALX148) | Phase 3 | Gastric Cancer | - | - |
evorpacept | Phase 2 | Head and Neck Cancer | - | - |
ALX148 | Phase 2 | Ovarian Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ALX ONCOLOGY HOLDINGS INC's drug pipeline?→
CatalystAlert tracks 3 drug candidates in ALX ONCOLOGY HOLDINGS INC's (ALXO) pipeline across Phase 3, Phase 2. Its lead program is Evorpacept (ALX148) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ALX ONCOLOGY HOLDINGS INC's next FDA catalyst?→
ALX ONCOLOGY HOLDINGS INC's (ALXO) next tracked catalyst is a Earnings expected November 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALXO biotech catalysts?→
Add ALXO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ALX ONCOLOGY HOLDINGS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.